Answers are grounded in this paper and cite their sources.
BACKGROUND: The best approach for H. pylori second- and third-line management remains unclear. The aim of this study was to evaluate the effectiveness and safety of second- and third-line H. pylori eradication regimens in Slovenia using a centralized registration database. METHODS: Patients second- and third-line eradication data from Slovenia registered in the European Registry on H. pylori Management (Hp-EuReg) from 2013 to 2024 were included. The regimens prescribed, the number of eradication attempts, effectiveness, adherence and safety were analyzed. The effectiveness was assessed by modified intention to treat (mITT). RESULTS: We have included 402 s-line and 81 third-line eradication regimens. By mITT analysis > 90% eradication rate for second-line regimens were achieved with 14 day quadruple regimen proton pump inhibitor (PPI) amoxicillin (A) levofloxacin (L) bismuth oxide (B) (95.7%; 95% CI 78.1%-99.9%),10 day and 14 day regimen with a PPI + A + L (90.9%, 95% CI 75.7%-98.1% and 90.2%, 95% CI 85.5%-94.9% respectively) and a 10-day regimen with a PPI combined with bismuth quadruple therapy as single capsule (100%, 95% CI 80.5%-100%). The overall eradication rate for second-line empirical treatments was 86% (95% CI 81.9%-90%), while for culture-guided treatments, it was 89.2% (95% CI 74.6%-97%; p > 0.05). In third-line treatment, the PPI and single-capsule combination therapy was the only regimen to achieve an optimal cure rate of 94.1% (95% CI 71.3%-99.9%). The eradication rate for empirical treatment was 84.4% (95% CI 72.7%-96.1%), while for culture-guided treatment it was 84.6% (95% CI 54.6%-98.1%; p > 0.05). Adverse effects were reported by 52 patients in second-line regimens (12.9%), and treatment was discontinued in 0.7% of cases, and by 12 patients (14.8%) in third-line regimens with no need for treatment discontinuation. CONCLUSIONS: In Slovenia, H. pylori eradication therapy appears to be effective and safe in real-world clinical practice. TRIAL REGISTRATION: Registered at ClinicalTrials. Gov (NCT02328131).
No takes yet. Share an insight, caveat, or question.
Tepeš et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: